Rein Therapeutics Inc. (NASDAQ:RNTX) Receives Average Rating of "Hold" from Analysts

Key Points

• Analyst sentiment is mixed: Rein Therapeutics has an average “Hold” rating from four analysts, with one sell, one hold, and two buy recommendations. The average 12-month price target is $6.00.
• Institutional ownership is high: Institutional investors hold 90.89% of the company, while several funds recently increased their stakes or initiated new positions.
• The stock remains under pressure: RNTX opened at $0.80 after declining 6%, near its 52-week low of $0.69. The company reported a quarterly loss of $0.10 per share, though this was better than the consensus estimate of a $0.27 loss.

Shares of Rein Therapeutics Inc. (NASDAQ:RNTX - Get Free Report) have received an average recommendation of "Hold" from the four ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $6.00.

Several research analysts recently weighed in on RNTX shares. Maxim Group began coverage on shares of Rein Therapeutics in a report on Monday, July 20th. They set a "buy" rating and a $4.00 price target on the stock. HC Wainwright reissued a "buy" rating on shares of Rein Therapeutics in a research report on Tuesday, August 18th. Weiss Ratings downgraded Rein Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, August 21st. Finally, Wall Street Zen raised Rein Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, June 6th.

Institutional Trading of Rein Therapeutics

Several hedge funds have recently added to or reduced their stakes in RNTX. Velan Capital Investment Management LP purchased a new position in Rein Therapeutics in the second quarter valued at about $1,768,000. Voss Capital LP increased its stake in shares of Rein Therapeutics by 59.2% during the 4th quarter. Voss Capital LP now owns 4,243,969 shares of the company's stock worth $4,923,000 after purchasing an additional 1,577,437 shares during the last quarter. Sequoia Financial Advisors LLC bought a new stake in shares of Rein Therapeutics in the 2nd quarter worth approximately $260,000. Chicago Partners Investment Group LLC lifted its stake in Rein Therapeutics by 32.2% in the first quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company's stock valued at $53,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Sigma Planning Corp lifted its stake in Rein Therapeutics by 41.0% in the first quarter. Sigma Planning Corp now owns 348,677 shares of the company's stock valued at $453,000 after purchasing an additional 101,400 shares during the last quarter. Institutional investors own 90.89% of the company's stock.

Rein Therapeutics Trading Down 6.0%

Rein Therapeutics stock opened at $0.80 on Friday. Rein Therapeutics has a 1-year low of $0.69 and a 1-year high of $2.18. The firm has a market capitalization of $69.08 million, a price-to-earnings ratio of -0.47 and a beta of 1.35. The firm's fifty day moving average price is $0.79 and its two-hundred day moving average price is $1.03.

Rein Therapeutics (NASDAQ:RNTX - Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17. On average, research analysts forecast that Rein Therapeutics will post -0.47 EPS for the current year.

About Rein Therapeutics

Rein Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for serious diseases with significant unmet medical needs. The company's research and development activities are centered on fibrotic diseases, in which excessive scar tissue can impair the function of organs and lead to progressive illness.

Rein Therapeutics' lead investigational program is RNTX-001, an experimental therapy being developed for pulmonary fibrosis and potentially other fibrotic conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.